Praxis Biologics vaccine grants
Two $50,000 Phase I Small Business Innovation Research grants received by firm. The first, from the Natl. Institute of Allergies & Infectious Diseases, covers development of a new infant Haemophilus influenzae bacterial (HIB) vaccine. Praxis already markets a Hib conjugate vaccine, B-CAPSA-I, and has completed Phase II study for a successor compound. The second grant, from the U.S. Department of Agriculture, is for research on a vaccine for Salmonella and other infections in poultry.
You may also be interested in...
The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
New medicines under evaluation at the European Medicines Agency.